ATAGI recommendations

Use of high-dose influenza vaccine versus standard dose influenza vaccine in adults aged ≥65 years

Use of high-dose influenza vaccine versus adjuvanted influenza vaccine in adults aged ≥65 years

Use of adjuvanted influenza vaccine versus standard dose influenza vaccine in adults aged ≥65 years

Use of MDCK cell-derived influenza vaccine versus standard dose egg-based influenza vaccine in children aged 2–17 years

Use of MDCK cell-derived influenza vaccine versus standard dose egg-based influenza vaccine in people aged ≥18 years

 

High-dose influenza vaccine (Fluzone)

Compared with standard dose influenza vaccine in people aged ≥65 years

Compared with adjuvanted influenza vaccine for people aged ≥65 years

 

Adjuvanted influenza vaccine (Fluad Quad) 

Compared with standard dose influenza vaccine in adults aged ≥65 years

 

MDCK cell-derived influenza vaccine (Flucelvax Quad)

Compared with standard dose egg-based influenza vaccine in children aged 2–17 years

Compared with standard dose egg-based influenza vaccine in people aged ≥18 years

Note: These GRADE documents should be read as a supplement to Australian Immunisation Handbook recommendations.

View the Influenza disease chapter in the Handbook here
View the ATAGI advice on seasonal influenza vaccines in 2023 here

Last updated February 2024